{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T09:20:39Z","timestamp":1781601639004,"version":"3.54.5"},"reference-count":28,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2017,6,6]]},"abstract":"<jats:p>Guillain-Barr\u00e9 syndrome (GBS) is an immune-mediated disease characterised by evolving ascending limb weakness, sensory loss and areflexia. Two-thirds of GBS cases are associated with preceding infection. However, GBS has also been described in association with antitumour necrosis factor (TNF) therapies including infliximab and adalimumab for chronic inflammatory disorders such as rheumatoid arthritis, ankylosing spondylitis and inflammatory bowel disease. We present the case of a patient who developed GBS while undergoing treatment with adalimumab in combination with azathioprine for severe fistulising Crohn\u2019s disease, and review the literature on neurological adverse events that occur in association with anti-TNF therapy. We also propose an approach to the optimal management of patients who develop debilitating neurological sequelae in the setting of anti-TNF therapy.<\/jats:p>","DOI":"10.1136\/bcr-2017-219481","type":"journal-article","created":{"date-parts":[[2017,7,5]],"date-time":"2017-07-05T05:52:26Z","timestamp":1499233946000},"page":"bcr-2017-219481","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Guillain-Barr\u00e9 syndrome in association with antitumour necrosis factor therapy: a case of mistaken identity"],"prefix":"10.1136","volume":"2017","author":[{"given":"Kurvi","family":"Patwala","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Austin Health, Heidelberg, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Crump","sequence":"additional","affiliation":[{"name":"Department of Neurology, Austin Health, Heidelberg, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"De Cruz","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Austin Health, Heidelberg, Australia"},{"name":"Department of Medicine, The University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,7,5]]},"reference":[{"key":"2025082802274607000_2017.jul04_1.bcr-2017-219481.1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.5694\/j.1326-5377.2005.tb06998.x","article-title":"Tumour necrosis factor inhibitors","volume":"183","author":"Nash","year":"2005","journal-title":"Med J Aust"},{"key":"2025082802274607000_2017.jul04_1.bcr-2017-219481.2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ncl.2013.01.005","article-title":"Guillain-Barr\u00e9 syndrome and variants","volume":"31","author":"Dimachkie","year":"2013","journal-title":"Neurol Clin"},{"key":"2025082802274607000_2017.jul04_1.bcr-2017-219481.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00339-1"},{"key":"2025082802274607000_2017.jul04_1.bcr-2017-219481.4","doi-asserted-by":"publisher","DOI":"10.1086\/499969"},{"key":"2025082802274607000_2017.jul04_1.bcr-2017-219481.5","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W"},{"key":"2025082802274607000_2017.jul04_1.bcr-2017-219481.6","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200109)44:9<1977::AID-ART345>3.0.CO;2-6"},{"key":"2025082802274607000_2017.jul04_1.bcr-2017-219481.7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1155\/2006\/385789","article-title":"Tumour necrosis factor inhibitors and infection: what is there to know for infectious diseases physicians?","volume":"17","author":"Johnston","year":"2006","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"2025082802274607000_2017.jul04_1.bcr-2017-219481.8","article-title":"Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome","volume":"7","author":"Hughes","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2025082802274607000_2017.jul04_1.bcr-2017-219481.9","doi-asserted-by":"crossref","unstructured":"Rapha\u00ebl JC , Chevret S , Hughes RA , et al . Plasma exchange for Guillain-Barr\u00e9 syndrome. Cochrane Database Syst Rev 2002:CD001798.doi:10.1002\/14651858.CD001798","DOI":"10.1002\/14651858.CD001798"},{"key":"2025082802274607000_2017.jul04_1.bcr-2017-219481.10","article-title":"Corticosteroids for Guillain-Barr\u00e9 syndrome","volume":"3","author":"Hughes","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2025082802274607000_2017.jul04_1.bcr-2017-219481.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)09095-2"},{"key":"2025082802274607000_2017.jul04_1.bcr-2017-219481.12","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21584"},{"key":"2025082802274607000_2017.jul04_1.bcr-2017-219481.13","doi-asserted-by":"publisher","DOI":"10.1002\/art.21814"},{"key":"2025082802274607000_2017.jul04_1.bcr-2017-219481.14","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.043208"},{"key":"2025082802274607000_2017.jul04_1.bcr-2017-219481.15","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21051"},{"key":"2025082802274607000_2017.jul04_1.bcr-2017-219481.16","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/bjd.12572","article-title":"Development of chronic inflammatory demyelinating polyneuropathy in a patient receiving infliximab for psoriasis","volume":"170","author":"Foulkes","year":"2014","journal-title":"Br J Dermatol"},{"key":"2025082802274607000_2017.jul04_1.bcr-2017-219481.17","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.jocn.2012.12.016","article-title":"Successful treatment of infliximab-associated immune-mediated sensory polyradiculopathy with intravenous immunoglobulin","volume":"20","author":"Naruse","year":"2013","journal-title":"J Clin Neurosci"},{"key":"2025082802274607000_2017.jul04_1.bcr-2017-219481.18","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-009-1174-3"},{"issue":"(Suppl 1)","key":"2025082802274607000_2017.jul04_1.bcr-2017-219481.19","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1007\/s10067-009-1154-7","article-title":"Guillain-Barre in a patient with ankylosing spondylitis secondary to ulcerative colitis on infliximab therapy","volume":"28","author":"Bouchra","year":"2009","journal-title":"Clin Rheumatol"},{"key":"2025082802274607000_2017.jul04_1.bcr-2017-219481.20","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000158681.29117.8B"},{"key":"2025082802274607000_2017.jul04_1.bcr-2017-219481.21","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1001\/jamaneurol.2015.2251","article-title":"Novel variant of Miller Fisher syndrome occurring with tumor necrosis factor \u03b1 antagonist therapy","volume":"72","author":"Ratnarajan","year":"2015","journal-title":"JAMA Neurol"},{"key":"2025082802274607000_2017.jul04_1.bcr-2017-219481.22","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-211781","article-title":"DADS neuropathy associated with anti-TNF-\u03b1 therapy","volume":"2015","author":"McGinty","year":"2015","journal-title":"BMJ Case Rep"},{"key":"2025082802274607000_2017.jul04_1.bcr-2017-219481.23","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s10067-013-2272-9","article-title":"Severe Guillain-Barr\u00e9 syndrome in a patient receiving anti-TNF therapy. consequence or coincidence. A case-based review","volume":"32","author":"Alvarez-Lario","year":"2013","journal-title":"Clin Rheumatol"},{"key":"2025082802274607000_2017.jul04_1.bcr-2017-219481.24","first-page":"401","article-title":"Meningeal and Guillain-Barr\u00e9 syndrome in a patient with rheumatoid arthritis receiving adalimumab therapy","volume":"7","author":"L\u00f3pez M\u00e9ndez","year":"2011","journal-title":"Rheumatol Clin"},{"key":"2025082802274607000_2017.jul04_1.bcr-2017-219481.25","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/CND.0b013e3181fd9401","article-title":"Steroid-induced inflammatory neuropathy in a patient on tumor necrosis factor-\u03b1 antagonist therapy","volume":"12","author":"Wong","year":"2010","journal-title":"J Clin Neuromuscul Dis"},{"key":"2025082802274607000_2017.jul04_1.bcr-2017-219481.26","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-008-1017-7"},{"key":"2025082802274607000_2017.jul04_1.bcr-2017-219481.27","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.08.2011.4674","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy complicating anti TNF \u03b1 therapy for chronic plaque psoriasis","volume":"2011","author":"Ahmed","year":"2011","journal-title":"BMJ Case Rep"},{"key":"2025082802274607000_2017.jul04_1.bcr-2017-219481.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2011.06.010"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2017-219481","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T09:27:56Z","timestamp":1756373276000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2017-219481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,5]]},"references-count":28,"alternative-id":["10.1136\/bcr-2017-219481"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2017-219481","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,5]]}}}